Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/59818
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMyllymaa, S.en
dc.contributor.authorPasternack, A.en
dc.contributor.authorMottershead, D.en
dc.contributor.authorPoutanen, M.en
dc.contributor.authorPulkki, M.en
dc.contributor.authorPelliniemi, L.en
dc.contributor.authorRitvos, O.en
dc.contributor.authorLaitinen, M.en
dc.date.issued2010en
dc.identifier.citationReproduction, 2010; 139(3):587-598en
dc.identifier.issn1470-1626en
dc.identifier.issn1741-7899en
dc.identifier.urihttp://hdl.handle.net/2440/59818-
dc.description.abstractGrowth differentiation factor-9 (GDF9) and bone morphogenetic protein-15 (BMP15) are among the key regulators transmitting the signaling between the oocyte and the surrounding granulosa cells. Previously, it has been shown that a recombinant BMP type II receptor ectodomain–Fc fusion protein (BMPR2ecd–Fc) is able to inhibit the actions of GDF9 and BMP15 in vitro. Here, we have produced bioactive BMPR2ecd–Fc, which was injected i.p. into neonatal mice. Early folliculogenesis was first studied by injecting mice five times with various doses of BMPR2ecd–Fc during the postnatal days 4–12. Folliculogenesis was affected dose dependently, as evidenced by a decreased mitogenesis of granulosa cells of the growing follicles. Furthermore, we also noticed a decrease in the number of secondary and tertiary follicles as well as an increase in the oocyte size. Electron microscopic analysis revealed that the ultrastructure of the granulosa cells of the primary follicles was not affected by the BMPR2ecd–Fc treatment. A second study was conducted to investigate whether a longer treatment with 12 injections during postnatal days 4–28 would inhibit folliculogenesis. Similar effects were observed in the two studies on the early follicular developmental stages. However, in the long-term study, later stages of folliculogenesis were not blocked but rather increased numbers of antral follicles, preovulatory follicles, and corpora lutea were found. We conclude that BMPR2ecd–Fc is a potent modulator of ovarian folliculogenesis in vivo, and thus, is a valuable tool for studying the physiology and downstream effects of oocyte-derived growth factors in vivo.en
dc.description.statementofresponsibilitySamu Myllymaa, Arja Pasternack, David G. Mottershead, Matti Poutanen, Minna M. Pulkki, Lauri J. Pelliniemi, Olli Ritvos and Mika P.E. Laitinenen
dc.language.isoenen
dc.publisherBio Scientifica Ltden
dc.rights© 2010 Society for Reproduction and Fertilityen
dc.subjectOvarian Follicle; Oocytes; CHO Cells; Animals; Animals, Newborn; Humans; Cricetulus; Mice; Intercellular Signaling Peptides and Proteins; Recombinant Fusion Proteins; Oogenesis; Sexual Maturation; Female; Cricetinae; Immunoglobulin Fc Fragments; Bone Morphogenetic Protein Receptors, Type II; Growth Differentiation Factor 9; Bone Morphogenetic Protein 15; Hep G2 Cellsen
dc.titleInhibition of oocyte growth factors in vivo modulates ovarian folliculogenesis in neonatal and immature miceen
dc.typeJournal articleen
dc.identifier.rmid0020095368en
dc.identifier.doi10.1530/REP-09-0391en
dc.identifier.pubid35792-
pubs.library.collectionObstetrics and Gynaecology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.